Literature DB >> 33413165

Design and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment.

Yara van Holstein1, Floor J van Deudekom2, Stella Trompet2, Iris Postmus2, Anna Uit den Boogaard2, Marjan J T van der Elst2, Nienke A de Glas3, Diana van Heemst2, Geert Labots4, Mariëtte Altena5, Marije Slingerland3, Gerrit Jan Liefers6, Frederiek van den Bos2, Jessica M van der Bol7, Gerard J Blauw2, Johanneke E A Portielje3, Simon P Mooijaart2,8.   

Abstract

BACKGROUND: Treatment decisions concerning older patients can be very challenging and individualised treatment plans are often required in this very heterogeneous group. In 2015 we have implemented a routine clinical care pathway for older patients in need of intensive treatment, including a comprehensive geriatric assessment (CGA) that was used to support clinical decision making. An ongoing prospective cohort study, the Triaging Elderly Needing Treatment (TENT) study, has also been initiated in 2016 for participants in this clinical care pathway, to study associations between geriatric characteristics and outcomes of treatment that are relevant to older patients. The aim of this paper is to describe the implementation and rationale of the routine clinical care pathway and design of the TENT study.
METHODS: A routine clinical care pathway has been designed and implemented in multiple hospitals in the Netherlands. Patients aged ≥70 years who are candidates for intensive treatments, such as chemotherapy, (chemo-)radiation therapy or major surgery, undergo frailty screening based on the Geriatric 8 (G-8) questionnaire and the Six-Item Cognitive Impairment Test (6CIT). If screening reveals potential frailty, a CGA is performed. All patients are invited to participate in the TENT study. Clinical data and blood samples for biomarker studies are collected at baseline. During follow-up, information about treatment complications, hospitalisations, functional decline, quality of life and mortality is collected. The primary outcome is the composite endpoint of functional decline or mortality at 1 year. DISCUSSION: Implementation of a routine clinical care pathway for older patients in need of intensive treatment provides the opportunity to study associations between determinants of frailty and outcomes of treatment. Results of the TENT study will support individualised treatment for future patients. TRIAL REGISTRATION: The study is retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107 . Date of registration: 22-10-2019.

Entities:  

Keywords:  Aortic valve replacement; Colon cancer; Comprehensive geriatric assessment; Frailty; Geriatric oncology; Head and neck cancer; Oesophageal cancer; Older patients; Study protocol

Mesh:

Year:  2021        PMID: 33413165      PMCID: PMC7791733          DOI: 10.1186/s12877-020-01975-0

Source DB:  PubMed          Journal:  BMC Geriatr        ISSN: 1471-2318            Impact factor:   3.921


  63 in total

1.  Health-Related Quality of Life at Admission Is Associated with Postdischarge Mortality, Functional Decline, and Institutionalization in Acutely Hospitalized Older Medical Patients.

Authors:  Juliette L Parlevliet; Janet MacNeil-Vroomen; Bianca M Buurman; Sophia E de Rooij; Judith E Bosmans
Journal:  J Am Geriatr Soc       Date:  2016-04       Impact factor: 5.562

2.  Time to Stop Saying Geriatric Assessment Is Too Time Consuming.

Authors:  Marije E Hamaker; Tanya M Wildes; Siri Rostoft
Journal:  J Clin Oncol       Date:  2017-06-19       Impact factor: 44.544

3.  Optimization of the APOP screener to predict functional decline or mortality in older emergency department patients: Cross-validation in four prospective cohorts.

Authors:  J de Gelder; J A Lucke; L C Blomaard; A M Booijen; A J Fogteloo; S Anten; E W Steyerberg; J Alsma; S C E Klein Nagelvoort Schuit; A Brink; B de Groot; G J Blauw; S P Mooijaart
Journal:  Exp Gerontol       Date:  2018-06-20       Impact factor: 4.032

4.  Assessment of older people: self-maintaining and instrumental activities of daily living.

Authors:  M P Lawton; E M Brody
Journal:  Gerontologist       Date:  1969

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test.

Authors:  M F Scheier; C S Carver; M W Bridges
Journal:  J Pers Soc Psychol       Date:  1994-12

7.  Depressive symptoms and 3-year mortality in older hospitalized medical patients.

Authors:  K E Covinsky; E Kahana; M H Chin; R M Palmer; R H Fortinsky; C S Landefeld
Journal:  Ann Intern Med       Date:  1999-04-06       Impact factor: 25.391

Review 8.  Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer.

Authors:  Enrique Soto-Perez-de-Celis; Daneng Li; Yuan Yuan; Yat Ming Lau; Arti Hurria
Journal:  Lancet Oncol       Date:  2018-06-01       Impact factor: 41.316

9.  Inclusion and analysis of older adults in RCTs.

Authors:  W Van de Water; E Bastiaannet; C J H Van de Velde; G J Liefers
Journal:  J Gen Intern Med       Date:  2011-08       Impact factor: 5.128

Review 10.  External validity of randomized controlled trials in older adults, a systematic review.

Authors:  Floor J van Deudekom; Iris Postmus; Danielle J van der Ham; Alexander B Pothof; Karen Broekhuizen; Gerard J Blauw; Simon P Mooijaart
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

View more
  1 in total

1.  Design of a consensus-based geriatric assessment tailored for older chronic kidney disease patients: results of a pragmatic approach.

Authors:  Carlijn G N Voorend; Hanneke Joosten; Noeleen C Berkhout-Byrne; Adry Diepenbroek; Casper F M Franssen; Willem Jan W Bos; Marjolijn Van Buren; Simon P Mooijaart
Journal:  Eur Geriatr Med       Date:  2021-04-19       Impact factor: 1.710

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.